Treatment of cognitive impairment in patients with multiple sclerosis

Expert Opinion on Investigational Drugs

Volumn 21, Issue 11, 2012, Pages 1679-1699

  Patti, Francesco ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Cognitive impairment; Cognitive rehabilitation; Disease modifying drugs; Multiple sclerosis; Symptomatic therapies; Treatment

Indexed keywords

4 AMINOPYRIDINE; AMPHETAMINE; BETA1A INTERFERON; CANNABIS; DEXAMPHETAMINE; DONEPEZIL; FINGOLIMOD; GINKGO BILOBA EXTRACT; GLATIRAMER; INTERFERON BETA SERINE; MEMANTINE; METHYLPHENIDATE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; RIVASTIGMINE;

AEROBIC EXERCISE; AGGRESSION; BRAIN ATROPHY; COGNITIVE DEFECT; COGNITIVE REHABILITATION; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FATIGUE; HUMAN; INTELLIGENCE; LOW DRUG DOSE; MENTAL PATIENT; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TEST; PARANOIA; PERFORMANCE; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; WORKING MEMORY;

ADJUVANTS, IMMUNOLOGIC; COGNITION; COGNITION DISORDERS; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TESTS;

EID: 84867543540     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.716036     Document Type: Review

References (142)

1. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology 1996;46:907-11
2. Amato MP, Zipoli V, Portaccio E. Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies. J Neurol Sci 2006;245:41-6
3. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991;41:685-91
4. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002;15:239-45
5. Horakova D, Kalincik T, Dusankova JB, Dolezal O. Clinical correlates of grey matter pathology in multiple sclerosis. BMC Neurol 2012;12:10
6. Vercellino M, Plano F, Votta B, et al. Grey matter pathology in multiple sclerosis. J Neuropathol Exp Neurol 2005;64:1101-7
7. Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 2001;58:1602-6
8. Glanz BI, Healy BC, Hviid LE, et al. Cognitive deterioration in patients with early multiple sclerosis: a 5-year study. J Neurol Neurosurg Psychiatry 2012;83:38-43
9. Calabrese M, Agosta F, Rinaldi F, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 2009;66:1144-50
10. Patti F, Amato M, Trojano M, et al. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Mult Scler 2009;15:779-88
11. Amato MP, Hakiki B, Goretti B, et al. Association of MRI metrics and cognitive impairment in radiologically isolated syndromes. Neurology 2012;78:309-14
12. Calabrese M, Rinaldi F, Grossi P, Gallo P. Cortical pathology and cognitive impairment in multiple sclerosis. Expert Rev Neurother 2011;11:425-32
13. Nocentini U, Bozzali M, Spano B, et al. Exploration of the relationships between regional grey matter atrophy and cognition in multiple sclerosis. Brain Imaging Behav 2012;Published online May 15 2012; doi: 10.1007/s11682-012-9170-7
14. Ghaffar O, Feinstein A. The neuropsychiatry of multiple sclerosis: a review of recent developments. Curr Opin Psychiatry 2007;20:278-85
15. Patel Y, Bhise V, Krupp L. Pediatric multiple sclerosis. Ann Indian Acad Neurol 2009;12:238-45
16. Amato MP, Goretti B, Ghezzi A, et al. Cognitive and psychosocial features of childhood and juvenile MS. Neurology 2008;70:1891-7
17. Amato MP, Goretti B, Ghezzi A, et al. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology 2010;75:1134-40
18. Hakim EA, Bakheit AM, Bryant TN, et al. The social impact of multiple sclerosis-a study of 305 patients and their relatives. Disabil Rehabil 2000;22:288-93
19. Patti F. Cognitive impairment in multiple sclerosis. Mult Scler 2009;15:2-8
20. Benito-Leon J, Morales JM, Rivera-Navarro J. Health-related quality of life and its relationship to cognitive and emotional functioning in multiple sclerosis patients. Eur J Neurol 2002;9:497-502
21. Benedict RH, Fischer JS, Archibald CJ, et al. Minimal neuropsychological assessment of MS patients: a consensus approach. Clin Neuropsychol 2002;16:381-97
22. Sartori E, Edan G. Assessment of cognitive dysfunction in multiple sclerosis. J Neurol Sci 2006;245:169-75
23. Boringa JB, Lazeron RH, Reuling IE, et al. The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice. Mult Scler 2001;7:263-7
24. Benedict RH, Cookfair D, Gavett R, et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 2006;12:549-58
25. Gronwall DM. Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills 1977;44:367-73
26. Smith A. Symbol digit modalities test (SDMT). Western Psychological Services; Los Angeles: 1982
27. Benton AL. Interactive effects of age and brain disease on reaction time. Arch Neurol 1977;34:369-70
28. Sternberg S. Memory-scanning: mental processes revealed by reaction-time experiments. Am Sci 1969;57:421-57
29. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935;18:643-62
30. Delis DC, Kramer JH, Ober BA. California verbal learning test manual, adult versions. 2nd edition. Psychological Corp; San Antonio, Texas: 2000
31. Benedict RHB. Brief visuospatial memory test-revised: professional manual. Psychological Assessment Resources, Inc; Odessa, Florida: 1997
32. Wechsler D. Manual for the wechsler adult intelligence scale-revised. Psychological Corp; New York: 1981
33. Brown J. Some test of the decay theory of immediate memory. Q J Exp Psychol 1958;10:12-21
34. Peterson LR, Peterson MJ. Short-term retention of individual verbal items. J Exp Psychol 1959;58:193-8
35. Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 1974;24:1019-25
36. Caine ED, Bamford KA, Schiffer RB, et al. A controlled neuropsychological comparison of Huntington's disease and multiple sclerosis. Arch Neurol 1986;43:249-54
37. Barbizet J, Cany E. Clinical and psychometrical study of a patient with memory disturbances. Int J Neurol 1968;7:44-54
38. Nelson LM, Franklin GM, Hamman RF, et al. Referral bias in multiple sclerosis research. J Clin Epidemiol 1988;41:187-92
39. Benton AL, Hamsher K. Multilingual aphasia examination. University of Iowa; Iowa City: 1976
40. Bayles KA, Kaszniak AW, Tomoeda CK. Communication and cognition in normal aging and dementia. College Hill Press; Boston: 1987
41. Rao S. Cognitive Function Study Group N. A Manual for the brief repeatable battery of neuropsychological tests in multiple sclerosis. National Multiple Sclerosis Society; New York: 1990
42. Hooper HE. The Hooper visual organization test manual. Western Psychological Services; Los Angeles: 1958
43. Benton AL, Hamsher K, Verney NR, Spreen O. Contributions to neuropsychological assessment: a clinical manual. Oxford University Press; New York: 1983
44. Delis DC, Kaplan E, Kramer JH. Delis-Kaplan executive function system. Psychological Corp; San Antonio, Texas: 2001
45. Heaton RK. Wisconsin card sorting test manual. Psychological Assessment Resources; Odessa, Florida: 1981
46. DeFilippis NA, McCampbell E. The booklet category test manual. Psychological Assessment Resources; Odessa, Florida: 1979
47. Raven JC. Guide to the standard progressive matrices. HK Lewis; London: 1960
48. Strober L, Englert J, Munschauer F, et al. Sensitivity of conventional memory tests in multiple sclerosis: comparing the rao brief repeatable neuropsychological battery and the minimal assessment of cognitive function in MS. Mult Scler 2009;15:1077-84
49. Langdon D, Amato M, Boringa J, et al. Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler 2012;18:891-8
50. Benedict RH, Munschauer F, Linn R, et al. Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire. Mult Scler 2003;9:95-101
51. Edgar C, Jongen PJ, Sanders E, et al. Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive battery. BMC Neurol 2011;11:68
52. Wilken JA, Kane R, Sullivan CL, et al. The utility of computerized neuropsychological assessment of cognitive dysfunction in patients with relapsing-remitting multiple sclerosis. Mult Scler 2003;9:119-27
53. Fredrickson J, Maruff P, Woodward M, et al. Evaluation of the usability of a brief computerized cognitive screening test in older people for epidemiological studies. Neuroepidemiology 2010;34:65-75
54. Gur RC, Richard J, Hughett P, et al. A cognitive neuroscience-based computerized battery for efficient measurement of individual differences: standardization and initial construct validation. J Neurosci Methods 2010;187:254-62
55. Patti F, Amato MP, Trojano M, et al. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study. Mult Scler J 2011;17:991-1001
56. Albert SM, Michaels K, Padilla M, et al. Functional significance of mild cognitive impairment in elderly patients without a dementia diagnosis. Am J Geriatr Psychiatry 1999;7:213-20
57. Kinsinger SW, Lattie E, Mohr DC. Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with multiple sclerosis. Neuropsychology 2010;24:573-80
58. Langdon DW. Cognition in multiple sclerosis. Curr Opin Neurol 2011;24:244-9
59. Solari A, Radice D, Manneschi L, et al. The multiple sclerosis functional composite: different practice effects in the three test components. J Neurol Sci 2005;228:71-4
60. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
61. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94
62. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsingremitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995;45:1268-76
63. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
64. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
65. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504
66. Pliskin NH, Hamer DP, Goldstein DS, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 1996;47:1463-8
67. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987-97
68. Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple sclerosis collaborative research group. Ann Neurol 2000;48:885-92
69. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002;59:679-87
70. Weinstein A, Schwid SI, Schiffer RB, et al. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999;56:319-24
71. Schwid SR, Goodman AD, Weinstein A, et al. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial. J Neurol Sci 2007;255:57-63
72. Weinstock-Guttman B, Galetta SL, Giovannoni G, et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. J Neurol 2012;259:898-905
73. Pelletier J, Karlsson G, Li B, et al. Effect of fingolimod on Multiple Sclerosis Functional Composite (MSFC) defined disability progression in patients with relapsing remitting MS (RRMS): results from two Phase III studies. Neurology 2011;76(Suppl 4):A611
74. Barak Y, Achiron A. Effect of interferon-beta-1b on cognitive functions in multiple sclerosis. Eur Neurol 2002;47:11-14
75. Flechter S, Vardi J, Finkelstein Y, Pollak L. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study. Isr Med Assoc J 2007;9:457-9
76. Patti F, Amato MP, Bastianello S, et al. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Mult Scler 2010;16:68-77
77. Zephir H, de SJ, Dujardin K, et al. Cognitive impact of mitoxantrone and methylprednisolone in multiple sclerosis: an open label study [in French]. Rev Neurol (Paris) 2008;164:47-52
78. Schroder A, Klotz P, Lee DH, et al. Stability of cognitive functions under mitoxantrone therapy in patients with progressive multiple sclerosis: a pilot analysis. Clin Neurol Neurosurg 2011;113:527-30
79. Mattioli F, Stampatori C, Capra R. The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study. Neurol Sci 2011;32:83-8
80. Mattioli F, Stampatori C, Bellomi F, Capra R. Natalizumab efficacy on cognitive impairment in MS. Neurol Sci 2011;31(Suppl 3):321-3
81. Basso MR, Bornstein RA, Lang JM. Practice effects on commonly used measures of executive function across twelve months. Clin Neuropsychol 1999;13:283-92
82. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9
83. PRISMS Study Group. University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-36
84. Amato MP, Zipoli V, Goretti B, et al. Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. J Neurol 2006;253:1054-9
85. Patti F, Amato MP, Trojano M, et al. Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II). Qual Life Res 2011;Published online 28 September 2011; doi: 10.1007/s11136-011-0021-6
86. Berger JR. Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies. Am J Manag Care 2011;17(Suppl 5):S146-53
87. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23
88. Barkhof F, Cohen JA, Montalban X, et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta-1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Mult Scler J 2011;17(Suppl):S406
89. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010;33:91-101
90. Lanni C, Lenzken SC, Pascale A, et al. Cognition enhancers between treating and doping the mind. Pharmacol Res 2008;57:196-213
91. Krupp LB, Christodoulou C, Melville P, et al. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 2004;63:1579-85
92. Krupp LB, Christodoulou C, Melville P, et al. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology 2011;76:1500-7
93. Shaygannejad V, Janghorbani M, Ashtari F, et al. Effects of rivastigmine on memory and cognition in multiple sclerosis. Can J Neurol Sci 2008;35:476-81
94. Villoslada P, Arrondo G, Sepulcre J, et al. Memantine induces reversible neurologic impairment in patients with MS. Neurology 2009;72:1630-3
95. Lovera JF, Frohman E, Brown TR, et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler 2010;16:715-23
96. Benedict RH, Munschauer F, Zarevics P, et al. Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients. J Neurol 2008;255:848-52
97. Morrow SA, Kaushik T, Zarevics P, et al. The effects of L-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial. J Neurol 2009;256:1095-102
98. Harel Y, Appleboim N, Lavie M, Achiron A. Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process. J Neurol Sci 2009;276:38-40
99. Smits RC, Emmen HH, Bertelsmann FW, et al. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology 1994;44:1701-5
100. Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-41
101. Aragona M, Onesti E, Tomassini V, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharmacol 2009;32:41-7
102. Ghaffar O, Feinstein A. Multiple sclerosis and cannabis: a cognitive and psychiatric study. Neurology 2008;71:164-9
103. Honarmand K, Tierney MC, O'Connor P, Feinstein A. Effects of cannabis on cognitive function in patients with multiple sclerosis. Neurology 2011;76:1153-60
104. Lovera J, Bagert B, Smoot K, et al. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial. Mult Scler 2007;13:376-85
105. Parry AM, Scott RB, Palace J, et al. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain 2003;126:2750-60
106. Huolman S, Hamalainen P, Vorobyev V, et al. The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue. Mult Scler 2011;17:1351-61
107. Thomas SJ, Grossberg GT. Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin Interv Aging 2009;4:367-77
108. Takon I. Clinical use of a modified release methylphenidate in the treatment of childhood attention deficit hyperactivity disorder. Ann Gen Psychiatry 2011;10:25
109. Pietrzak RH, Snyder PJ, Maruff P. Use of an acute challenge with d-amphetamine to model cognitive improvement in chronic schizophrenia. Hum Psychopharmacol 2010;25:353-8
110. Barch DM, Carter CS. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res 2005;77:43-58
111. Sumowski JF, Chiaravalloti N, Erlanger D, et al. L-amphetamine improves memory in MS patients with objective memory impairment. Mult Scler 2011;17:1141-5
112. Blight AR. Treatment of walking impairment in multiple sclerosis with dalfampridine. Ther Adv Neurol Disord 2011;4:99-109
113. Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009;373:732-8
114. Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010;68:494-502
115. Weinmann S, Roll S, Schwarzbach C, et al. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr 2010;10:14
116. Johnson SK, Diamond BJ, Rausch S, et al. The effect of Ginkgo biloba on functional measures in multiple sclerosis: a pilot randomized controlled trial. Explore (NY) 2006;2:19-24
117. Lakhan SE, Rowland M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurol 2009;9:59
118. O'Brien AR, Chiaravalloti N, Goverover Y, DeLuca J. Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature. Arch Phys Med Rehabil 2008;89:761-9
119. Chiaravalloti ND, DeLuca J, Moore NB, Ricker JH. Treating learning impairments improves memory performance in multiple sclerosis: a randomized clinical trial. Mult Scler 2005;11:58-68
120. Allen DN, Longmore S, Goldstein G. Memory training and multiple sclerosis: a case study. Int J Rehabil Health 1995;1:189-202
121. Chiaravalloti ND, DeLuca J. Self-generation as a means of maximizing learning in multiple sclerosis: an application of the generation effect. Arch Phys Med Rehabil 2002;83:1070-9
122. Basso MR, Lowery N, Ghormley C, et al. Self-generated learning in people with multiple sclerosis. J Int Neuropsychol Soc 2006;12:640-8
123. Shatil E, Metzer A, Horvitz O, Miller A. Home-based personalized cognitive training in MS patients: a study of adherence and cognitive performance. NeuroRehabilitation 2010;26:143-53
124. d'Amato T, Bation R, Cochet A, et al. A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia. Schizophr Res 2011;125:284-90
125. Elkins JS, Longstreth WT Jr, Manolio TA, et al. Education and the cognitive decline associated with MRI-defined brain infarct. Neurology 2006;67:435-40
126. Stern Y, Alexander GE, Prohovnik I, Mayeux R. Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer's disease. Ann Neurol 1992;32:371-5
127. Stern Y. Cognitive reserve. Neuropsychologia 2009;47:2015-28
128. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 2002;8:448-60
129. Sumowski JF, Wylie GR, Chiaravalloti N, DeLuca J. Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis. Neurology 2010;74:1942-5
130. Sumowski JF, Wylie GR, DeLuca J, Chiaravalloti N. Intellectual enrichment is linked to cerebral efficiency in multiple sclerosis: functional magnetic resonance imaging evidence for cognitive reserve. Brain 2010;133:362-74
131. Sumowski JF, Wylie GR, Gonnella A, et al. Premorbid cognitive leisure independently contributes to cognitive reserve in multiple sclerosis. Neurology 2010;75:1428-31
132. Prakash RS, Snook EM, Motl RW, Kramer AF. Aerobic fitness is associated with gray matter volume and white matter integrity in multiple sclerosis. Brain Res 2010;1341:41-51
133. Huisinga JM, Filipi ML, Stergiou N. Elliptical exercise improves fatigue ratings and quality of life in patients with multiple sclerosis. J Rehabil Res Dev 2011;48:881-90
134. Oken BS, Kishiyama S, Zajdel D, et al. Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology 2004;62:2058-64
135. Velikonja O, Curic K, Ozura A, Jazbec SS. Influence of sports climbing and yoga on spasticity, cognitive function, mood and fatigue in patients with multiple sclerosis. Clin Neurol Neurosurg 2010;112:597-601
136. Motl RW, Gappmaier E, Nelson K, Benedict RH. Physical activity and cognitive function in multiple sclerosis. J Sport Exerc Psychol 2011;33:734-41
137. Caggiula M, Batocchi AP, Frisullo G, et al. Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. Clin Immunol 2006;118:77-82
138. Biernacki K, Antel JP, Blain M, et al. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch Neurol 2005;62:563-8
139. Lindquist S, Hassinger S, Lindquist JA, Sailer M. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment. Mult Scler 2011;17:851-66
140. Schwid SR, Bever CT. The cost of delaying treatment in multiple sclerosis: what is lost is not regained. Neurology 2001;56:1620
141. Portaccio E, Goretti B, Zipoli V, et al. A short version of Rao's Brief Repeatable Battery as a screening tool for cognitive impairment in multiple sclerosis. Clin Neuropsychol 2009;23:268-75
142. Turpin KV, Carroll LJ, Cassidy JD, Hader WJ. Deterioration in the health-related quality of life of persons with multiple sclerosis: the possible warning signs. Mult Scler 2007;13:1038-45